Literature DB >> 23975519

Are regimens containing rituximab effective in the initial treatment of Epstein-Barr virus-positive natural killer cell lymphoproliferative disease-associated hemophagocytic lymphohistiocytosis?

Shinsaku Imashuku1, Naoko Kudo, Kagekatsu Kubo, Akihiro Yachie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23975519     DOI： 10.1007/s12185-013-1419-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

Review 1.  Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases.

Authors:  S Imashuku; S Hibi; Y Tabata; E Itoh; T Hashida; K Tsunamoto; K Ishimoto; F Kawano
Journal:  Leuk Lymphoma       Date:  2000-05

2.  Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010.

Authors:  Shinsaku Imashuku
Journal:  J Pediatr Hematol Oncol       Date:  2011-01       Impact factor: 1.289

3.  Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy.

Authors:  Michael C Milone; Donald E Tsai; Richard L Hodinka; Lewis B Silverman; Alejandro Malbran; Mariusz A Wasik; Kim E Nichols
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

4.  EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases.

Authors:  Hiroshi Kimura; Yoshinori Ito; Shinji Kawabe; Kensei Gotoh; Yoshiyuki Takahashi; Seiji Kojima; Tomoki Naoe; Shinichi Esaki; Atsushi Kikuta; Akihisa Sawada; Keisei Kawa; Koichi Ohshima; Shigeo Nakamura
Journal:  Blood       Date:  2011-11-16       Impact factor: 22.113

5.  Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.

Authors:  Naomi J Balamuth; Kim E Nichols; Michele Paessler; David T Teachey
Journal:  J Pediatr Hematol Oncol       Date:  2007-08       Impact factor: 1.289

6.  Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin.

Authors:  Karin Beutel; Ute Gross-Wieltsch; Thomas Wiesel; Udo Zur Stadt; Gritta Janka; Hans-Joachim Wagner
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

7.  Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults.

Authors:  Keiko Suzuki; Koichi Ohshima; Kennosuke Karube; Junji Suzumiya; Shouichi Ohga; Shigehiko Ishihara; Kazuo Tamura; Masahiro Kikuchi
Journal:  Int J Oncol       Date:  2004-05       Impact factor: 5.650

8.  Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.

Authors:  DeepakBabu Chellapandian; Rupali Das; Kristin Zelley; Susan J Wiener; Huaqing Zhao; David T Teachey; Kim E Nichols
Journal:  Br J Haematol       Date:  2013-05-21       Impact factor: 6.998
  8 in total
  1 in total

1.  PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Authors:  Jingshi Wang; Yini Wang; Lin Wu; Jia Zhang; Wenyuan Lai; Zhao Wang
Journal:  J Hematol Oncol       Date:  2016-09-09       Impact factor: 17.388
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.